AI models trained on optical coherence tomography scans to detect eye diseases are showing promise in diagnosing heart ...

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

The Series B financing will support an upcoming clinical trial in New Zealand of the company's lead program, EPI-321, in facioscapulohumeral muscular dystrophy.

Nanoscope Therapeutics has said it plans to seek regulatory approval for its advanced retinitis pigmentosa gene therapy MCO-010 early this year.

The firm will seek accelerated approval for WVE-N531 in DMD amenable to exon 53 skipping based on FDA feedback and Phase II data.

The firm says it has a path forward for a Phase II/III registration-enabling study of NOUS-209 after positive meetings with the FDA.

Merck will pay the Chinese pharma company $200 million upfront and up to $1.77 billion in development, regulatory, and commercial milestone payments.

If Anixa exercises its rights, Verdi and Anixa will collaborate on trials in the US, while Verdi will continue developing personalized vaccines in Europe.

The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.

NEW YORK – Cargo Therapeutics this week said it is suspending development of its CD19/CD20/CD21 tri-specific autologous CAR T-cell therapy CRG-023 in B-cell malignancies and reducing its workforce by ...

NEW YORK – Layer Health is developing its large language model (LLM)-based data abstraction platform as a tool to help doctors make individualized treatment decisions for patients using the totality ...

Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times ...